Funder: Agency for Science Technology and Research
Due Dates (Anticipated): August 2027 (Eligibility waiver) | August 2027 (Pre-Pilot full proposals) | August 2027 (Pilot pitch deck and write-up)
Funding Amounts: Pre-Pilot: up to S$325,000 for 1 year; Pilot: up to S$1 million for 2 years, including 30% indirect costs
Summary: Supports Singapore public-sector drug discovery and therapeutic platform projects through phased funding, mentoring, and commercialisation support.
Key Information: Lead PIs must hold at least a 0.7 FTE primary appointment at a Singapore publicly funded research or tertiary institution.
Description
The Singapore Therapeutics Development Review (STDR) is a national public-sector research grant implemented by A*STAR with the Experimental Drug Development Centre (EDDC), Nucleic Acid Therapeutics Initiative (NATi), and Singapore-MIT Alliance for Research and Technology (SMART). It aims to strengthen Singapore’s drug development and biotech pipelines through funding matched to project maturity and industry readiness, active project management, industry feedback, mentoring, training, and networking.
Pre-Pilot supports exploratory proof-of-concept work with preliminary data, through target validation and therapeutic platform development streams. Pilot supports more mature projects with robust target validation, sufficient research data, and a clear development and commercialisation pathway. STDR spans disease areas and modalities, including small molecules, biologics, cell and gene therapies, and asset-focused platforms. Projects must lead towards first- or best-in-class therapeutic assets.
